Search clinical trials for: Sperti Del Sol Lamp

Total 142 results

University of Nebraska

Completed

Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp

Vitamin D Deficiency | Short Bowel Syndrome

United States
Atlanta VA Medical Center
Emory University

Completed

Improving Vitamin D Status In Cystic Fibrosis

Cystic Fibrosis

United States
Alexandria University
Lehigh University

Completed

Bioactive Glass (Sol-gel) for Alveolar Bone Regeneration After Surgical Extraction

Bone Loss | Horizontal Alveolar Bone Loss | Vertical Alveolar Bone Loss

Egypt
Boston University

Completed

Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery

Gastrointestinal Diseases | Vitamin D Deficiency

United States
Aswan University Hospital

Not yet recruiting

Developmental Endothelial Locus-1, Platelet Count, and Soluble P-selectin in Overweight and Obese Subjects

Overweight and Obesity

Egypt
Selecta Biosciences, Inc.

Completed

Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

Gout

United States
University Hospital, Clermont-Ferrand
Institut ANALGESIA

Completed

E-health Tool for Management of Chronic Pain Patients. (e-DOL)

Chronic Pain

France
University of Virginia
Johns Hopkins Bloomberg School of Public Health; National Institute on Minority... and other collaborators

Recruiting

The R-CITY Project: A Collaborative Intervention With Teachers and Youth (R-CITY)

Violence

United States
Wilfrid Laurier University

Unknown

Orthotics and Parkinson's Disease: The Acute and Long-term Effects of Increased Somatosensory Feedback

Parkinson Disease

Canada
Swedish Orphan Biovitrum

Completed

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II (DISSOLVE II)

Chronic Gout

United States, Serbia, Georgia, Ukraine, Russian Federation
Dana-Farber Cancer Institute
Vera and Joseph Dresner Foundation

Completed

Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS

Myelodysplastic Syndromes

United States
Swedish Orphan Biovitrum

Completed

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy (DISSOLVE I)

Chronic Gout

United States
Selecta Biosciences, Inc.
National Human Genome Research Institute (NHGRI)

Suspended

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA (reiMMAgine)

Methylmalonic Acidemia (MMA)

United States
Selecta Biosciences, Inc.

Completed

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

Hyperuricemia | Gout Chronic

United States
Tuberculosis Clinical Diagnostics Research Consortium
University of Cape Town

Unknown

Feasibility of a Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in South Africa

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Miliary

South Africa
Gilead Sciences

Completed

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease (MOSAIC)

Diabetic Kidney Disease

United States, Japan, New Zealand, Australia, Canada
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4)

Nonalcoholic Steatohepatitis

United States, Spain, Hong Kong, Canada, Belgium, Australia, Taiwan, India, Japan, Korea, Republic of, Singapore, United Kingdom, Israel, Puerto Rico, France, New Zealand, Germany, Austria, Italy, Mexico, Poland, Switzerland
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR-3)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Spain, United Kingdom, Australia, Taiwan, Belgium, Canada, India, Japan, Korea, Republic of, Singapore, Puerto Rico, France, Israel, Austria, Germany, Italy, Malaysia, New Zealand, Mexico, Poland, Switzerland, Netherlan... and more
Selecta Biosciences, Inc.

Completed

Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

Gout

United States
Selecta Biosciences, Inc.

Completed

Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers

Smoking Cessation

Belgium
MediWound Ltd

Completed

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

Thermal Burns

United States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

Vaginal Infection

United States
Cairo University

Recruiting

Ozone Gel Application in Controlled Type 2 Diabetic Patients With Periodontitis

Periodontal Diseases

Egypt
Selecta Biosciences, Inc.

Completed

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy (COMPARE)

Chronic Gout

United States
Karyopharm Therapeutics Inc

Withdrawn

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Diabetic Foot Ulcers

New Zealand
Southwest Regional Wound Care Center
Next Science TM

Completed

The Clinical Efficacy of Next Science Wound Gel (NXTSC) in the Healing of Chronic Wounds

Wound Infection

United States
Kirby Institute

Completed

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. (REACT)

Hepatitis C

Australia, United States, United Kingdom, New Zealand, Switzerland, Canada, Germany, Netherlands
Lawson Health Research Institute
University of Western Ontario, Canada; London Regional Cancer Program, Canada

Terminated

SPECT-CT Guided Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) in Prostate Cancer

Prostate Cancer

Canada
Gilead Sciences

Completed

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Non-Alcoholic Steatohepatitis (NASH)

United States, Canada
Gilead Sciences

Terminated

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Hepatitis C Virus Infection

France, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
Gilead Sciences

Terminated

Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

Poland, Italy, United Kingdom
Georgetown University
Next Science TM

Completed

Investigation of a Novel Wound Gel to Improve Wound Healing in Chronic Wounds

Wound Infection

United States
Johns Hopkins University

Completed

deLIVER: Direct Acting Antiviral Effects on the Liver (deLIVER)

HIV | Liver Disease | HCV Coinfection

United States
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2)

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
National Cancer Institute (NCI)

Terminated

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Mesothelioma

United States
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (ATLAS)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Australia, Puerto Rico, New Zealand, Canada
Gilead Sciences

Completed

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

Korea, Republic of
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

China, Korea, Republic of, Taiwan
Gilead Sciences

Completed

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection (ASTRAL-3)

Hepatitis C Virus Infection

United States, France, New Zealand, Canada, Germany, Puerto Rico, United Kingdom, Australia, Italy
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C Virus Infection

Egypt
Istanbul University
Istanbul University Research Fund

Completed

Efficacy of Diode Laser in Peri-implantitis

Peri-Implantitis | Complications | Alveolar Bone Loss | Implant

Turkey
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Hepatitis C Virus Infection

United States, Puerto Rico
Gilead Sciences

Completed

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection (ASTRAL-2)

Hepatitis C Virus Infection

United States, Puerto Rico
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
University Hospital, Rouen

Unknown

Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools (RRMUT)

Developmental Disorders

France
MJM Bonten
Paris 12 Val de Marne University

Completed

Ecological Effects of Decolonisation Strategies in Intensive Care (RGNOSIS)

ICU-ecology (Multidrug Resistant Bacteria) | ICU-acquired Bacteraemia

Belgium, Spain, United Kingdom, Italy, Portugal, Slovenia
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
The Christ Hospital
Gilead Sciences

Completed

Transmission of Chronic Hepatitis C in Pregnancy

Hepatitis C | Pregnancy Complications | Vertical Disease Transmission

United States

3

Subscribe